Genmab (GMAB) presented its development pipeline at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The Danish biotech’s shares were trading at $33.04, close to the 52‑week high of $35.43, and have delivered a 23% total return over the past six months. The company carries a market capitalization of roughly $20.1 billion, a gross profit margin of 93% and reported 22% revenue growth year‑over‑year, earning a 3.25‑out of‑5 financial‑health score from InvestingPro.
The focus was on three late‑stage assets: epcoritamab (EPCO/EPKINLY), petosemtamab (Pito) and the folate‑receptor‑targeted antibody Rina‑S. For epcoritamab, data from the EPCORE DLBCL‑4 trial showed a 60% reduction in progression risk and a 56% reduction in death risk versus R‑GemOx, with a hazard ratio for progression‑free survival of 0.40‑0.44. Two‑year progression‑free survival in the control arm is about 65%, and overall survival sits between 70% and 75%.
Petosemtamab’s early‑stage results were also discussed. In a first‑line head‑and‑neck phase II proof‑of‑concept, the combination achieved a 63% overall response rate versus 51% for pembrolizumab alone in KEYNOTE‑048, and a 12‑month overall survival of 79% versus 51% for pembrolizumab. The HPV‑positive cohort responded in 50% of patients (4 of 8). In colorectal cancer, phase II studies reported response rates of 80% in first‑line and 62% in second‑line settings, with organoid data indicating a 100‑fold differential killing of tumor versus normal cells.
Rina‑S, aimed at folate‑receptor‑high gynecologic cancers, produced an 83% response rate in a small phase II cohort of six high‑expressing patients and a 50% response in ten low‑expressing patients. The drug is being positioned for platinum‑resistant ovarian cancer, an indication with an addressable U.S. population of roughly 27,000 patients. Peak‑sales potential for Rina‑S is estimated at DKK 2 billion.
Genmab said three major Phase III readouts are expected within the next six to twelve months, with the first‑line DLBCL‑02 study and the head‑and‑neck Project Frontrunner data slated for the fourth quarter of 2024. Rina‑S Phase III data in platinum‑resistant ovarian cancer are also targeted for Q4 2024. A label update in March removed the mandatory 25‑hour hospitalization requirement for third‑line epcoritamab.
The company’s chief development officer, Judith, emphasized the commercial upside of combining epcoritamab with R‑CHOP in first‑line diffuse large B‑cell lymphoma, describing the upcoming DLBCL‑02 readout as a “big commercial opportunity.” She also noted that the phase II data with pembrolizumab could “transform the landscape of head and neck treatment.”
